Detalhe da pesquisa
1.
Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Transplant Cell Ther
; 30(2): 213.e1-213.e12, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38042256
2.
Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Transplant Cell Ther
; 29(3): 181.e1-181.e10, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36526259
3.
PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Transplant Cell Ther
; 28(8): 489.e1-489.e9, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577323
4.
Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis.
Bone Marrow Transplant
; 55(7): 1264-1271, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103146
5.
A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe.
Bone Marrow Transplant
; 55(5): 965-973, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932656
6.
Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.
Bone Marrow Transplant
; 54(8): 1295-1303, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30664727